October 2017 - Volume 27 - Issue 5 - Contributor Index

Alphabetical Search
I
O
Q
U
X
Y

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas

Soares, Ciro D.; Borges, Camilla F.; Sena-Filho, Marcondes; More

Melanoma Research. 27(5):448-456, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Ashraf, Madeeha

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Author:
Ba, Hong-Jun
Author:
Bagot, Martine

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Author:
Bechter, Oliver

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

Rogiers, Aljosja; Borght, Sara Vander; Tuand, Krizia; More

Melanoma Research. 27(5):507-510, October 2017.

Author:
Behin, Anthony

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

Rogiers, Aljosja; Borght, Sara Vander; Tuand, Krizia; More

Melanoma Research. 27(5):507-510, October 2017.

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas

Soares, Ciro D.; Borges, Camilla F.; Sena-Filho, Marcondes; More

Melanoma Research. 27(5):448-456, October 2017.

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

Rogiers, Aljosja; Borght, Sara Vander; Tuand, Krizia; More

Melanoma Research. 27(5):507-510, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Author:
Bowen, Glen M.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Chira, Ciprian

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas

Soares, Ciro D.; Borges, Camilla F.; Sena-Filho, Marcondes; More

Melanoma Research. 27(5):448-456, October 2017.

Author:
Clementi, Marco

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Cohen, Adam L.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Ding, Ya
Author:
Emmett, Louise

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Author:
Furda, Robert
Author:
Furdova, Alena

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Garmyn, Marjan

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

Rogiers, Aljosja; Borght, Sara Vander; Tuand, Krizia; More

Melanoma Research. 27(5):507-510, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Author:
Graner, Edgard

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas

Soares, Ciro D.; Borges, Camilla F.; Sena-Filho, Marcondes; More

Melanoma Research. 27(5):448-456, October 2017.

Author:
Gregus, Michal

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Haase, Ozan
Author:
Hager, Henrik

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Homsi, Jade
Author:
Hyngstrom, John

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Jorge, Jacks

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas

Soares, Ciro D.; Borges, Camilla F.; Sena-Filho, Marcondes; More

Melanoma Research. 27(5):448-456, October 2017.

Author:
Khong, Hung

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Author:
Kofler, Lukas
Author:
Kralik, Gabriel

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Author:
Laly, Pauline

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Author:
Langan, Ewan A.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Author:
Li, Dan-Dan
Author:
Li, Jing-Jing
Author:
Lin, Hui-Min

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Author:
Lin, Yan

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
McMahon, Martin

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Meyer, Nicolas

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

Gardner, Laura J.; Ward, Morgan; Andtbacka, Robert H.I.; More

Melanoma Research. 27(5):477-484, October 2017.

Author:
Mourah, Samia

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination

Aboudaram, Amélie; Modesto, Anouchka; Chaltiel, Léonor; More

Melanoma Research. 27(5):485-491, October 2017.

Author:
Nieweg, Omgo E.
Author:
Pages, Cécile

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

Gauci, Marie-Léa; Laly, Pauline; Leonard-Louis, Sarah; More

Melanoma Research. 27(5):511-515, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Panelli, Monica

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

Tarhini, Ahmad A.; Floros, Theofanis; Lin, Hui-Min; More

Melanoma Research. 27(5):429-438, October 2017.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Author:
Puri, Akshjot
1 2 Next